Advancements in gene therapy using the Olympus Provi CM20 Incubation Monitoring System
2 Aug 2023
In this video, Eric Blackwood, the Senior Postdoctoral Fellow at the Translational Cardiovascular Research Center, shares insights into the center's research aimed at discovering novel therapeutics for heart failure. The focus lies on small molecule drug-based and gene therapy approaches, utilizing AAV 9 for their investigations. The researchers employ the Olympus Provi CM20 Incubation Monitoring System for monitoring cell proliferation, virus production, and tracking the differentiation of induced pluripotent stem cells into cardiac myocytes. With constant use and real-time monitoring capabilities, the Olympus System contributes to significant time savings and improved research planning, supporting their mission to develop effective treatments for heart failure.
About the company
EVIDENT
At Evident, we are guided by the scientific spirit—innovation and exploration are at the heart of what we do. Committed to making people’s lives healthier, safer and more fulfilling, we support our customers with solutions that solve their challenges and advance their work; whether it’s researching medical breakthroughs, inspecting infrastructure, or exposing hidden toxins in consumer products.
Evident Life Science empowers scientists and researchers through collaboration and cutting-edge life science solutions. Dedicated to meeting the challenges and supporting the evolving needs of its customers, Evident Life Science advances a comprehensive range of clinical research, educational, and premium microscopes and microscope systems.
For more information, visit EvidentScientific.com.
